Demonstration of Epstein-Barr virus in a case of multiple myeloma after renal transplantation.
Ancín
I
I
Sarrá
J
J
Peris
J
J
Romagosa
V
V
Domingo-Claros
A
A
Grañena
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D016867:Immunocompromised Host; D016130:Immunophenotyping; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009101:Multiple Myeloma / Q000209:etiology / Q000473:pathology / Q000821:virology*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012334:RNA, Neoplasm / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D012334:RNA, Neoplasm; D012367:RNA, Viral; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone